title: Efficacy of purified Anaplasma marginale initial bodies as a vaccine against anaplasmosis.
abstract: Anaplasma marginale initial bodies of the Florida strain were purified from infected erythrocytes using a combination of ultrasonic disruption, nonionic detergent and differential centrifugation. Immunochemical analysis revealed at least 12 A. marginale proteins in the molecular mass (m) range 81-15 kDa with a prominent band at 38 kDa. Several of these proteins remained insoluble in the presence of nonionic detergent. Preparations of purified Anaplasma initial bodies contained negligible erythrocytic contamination, as confirmed by the minimal induction of isoantibodies against bovine blood group antigens and the absence of delayed-type hypersensitivity to erythrocytic antigens in immunized animals. A total of 33 crossbred and purebred Holstein cattle were vaccinated with either 1.5, 1.0, or 0.1 mg protein of intact initial bodies, or with 1.0 mg of solubilized Anaplasma protein. The immunogens were supplemented with 3.0 mg Quil-A saponin adjuvant and administered in 2 subcutaneous injections given at a 4-week interval. A similar number of nonvaccinated cattle served as controls. Three months after vaccination, all cattle were challenged by inoculation of 10(9) virulent A. marginale of either the homologous (Florida) or heterologous (Venezuelan) strains. Vaccinated cattle showed solid protection after homologous and heterologous challenge, characterized by parasite clearance and minimal hematocrit reductions. Initial data from four field vaccine trials revealed a reduced incidence of clinical anaplasmosis among immunized animals. Use of immunogens consisting of purified A. marginale initial bodies offers a potential immunoprophylactic approach to control of bovine anaplasmosis.
authors.affiliation: Department of Tropical Medicine, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA 70112.
authors.forename: S
authors.initials: S
authors.lastname: Montenegro-James
authors.forename: M A
authors.initials: MA
authors.lastname: James
authors.forename: M T
authors.initials: MT
authors.lastname: Benitez
authors.forename: E
authors.initials: E
authors.lastname: Leon
authors.forename: B K
authors.initials: BK
authors.lastname: Baek
authors.forename: A T
authors.initials: AT
authors.lastname: Guillen
mesh_terms: D000709:Anaplasma / Q000276:immunology*; D000712:Anaplasmosis / Q000517:prevention & control*; D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis; D000942:Antigens, Bacterial / Q000032:analysis / Q000276:immunology; D001428:Bacterial Vaccines; D015153:Blotting, Western; D002417:Cattle; D002418:Cattle Diseases / Q000517:prevention & control*; D004591:Electrophoresis, Polyacrylamide Gel; D006968:Hypersensitivity, Delayed; D007111:Immunity, Cellular; D012995:Solubility
chemical_list: D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001428:Bacterial Vaccines